Johnson & Johnson (JNJ): FY24 Q4 earnings call, Jan 22, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jan 22, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
7 matches for “Europe”; 5 quoted, at least 25 words apart.
…points due to acquisitions and divestitures. It's important to note growth in Europe was negatively impacted by 720 basis points due to the loss of…
…and divestitures positively impacted worldwide growth by 50 basis points. Growth in Europe was negatively impacted by 670 basis points due to the COVID-19 vaccine…
…SIMPONI worldwide sales were positively impacted by return of distribution rights in Europe. In Neuroscience, SPRAVATO growth of 45.3% continues to be driven by increased…
…partially offset by inventory dynamics in the US and austerity measures in Europe. Starting in 2025, we will begin to report OPSYNVI, which is currently…
…setting as well as very strong capacity expansion in the US, in Europe and also with a contract manufacturer. And so we've talked before about…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-01-22:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-01-22:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP